George Washington University

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Retrieved on: 
Thursday, March 7, 2024

SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).

Key Points: 
  • SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).
  • Dr. Lenz accelerates translational and clinical research and provides training and mentoring in the design and implementation of investigator-initiated trials.
  • In 1991, he completed his internship, residency, and fellowship training at the Eberhardt Karls Universität in Tübingen, Germany.
  • “His insight and clinical experience as a leading expert in colorectal cancer is of great importance as we develop our SAFEbody® ADG126 for patients worldwide.”
    For more information about members of the Adagene Scientific and Strategic Advisory Board, visit: https://www.adagene.com/about/key-advisors/

Armada Hoffler Announces John W. Snow Will Retire From Company’s Board Of Directors

Retrieved on: 
Monday, March 4, 2024

VIRGINIA BEACH, Va., March 04, 2024 (GLOBE NEWSWIRE) -- Armada Hoffler (NYSE: AHH) announced that John W. Snow, 84, will retire as a member of the Company’s Board of Directors effective as of the date of Armada Hoffler’s 2024 Annual Meeting of Stockholders.

Key Points: 
  • VIRGINIA BEACH, Va., March 04, 2024 (GLOBE NEWSWIRE) -- Armada Hoffler (NYSE: AHH) announced that John W. Snow, 84, will retire as a member of the Company’s Board of Directors effective as of the date of Armada Hoffler’s 2024 Annual Meeting of Stockholders.
  • Armada Hoffler’s Board of Directors recently approved an amendment to Armada Hoffler’s Corporate Governance Guidelines pursuant to which directors will no longer stand for re-election after they reach the age of 80.
  • “I have greatly enjoyed my time with Armada Hoffler and am proud to have served on the board since the IPO,” said John Snow.
  • “John has been a dedicated and valuable member of our Board of Directors, and we are deeply grateful for his guidance, leadership and service,” said Lou Haddad, CEO of Armada Hoffler.

Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

Retrieved on: 
Monday, March 4, 2024

Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck.

Key Points: 
  • Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck.
  • “It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.
  • Following the next clinical updates expected mid-year, we anticipate continued expansion of and future pivotal studies for SL-172154 in multiple indications.
  • Dr. Sasser holds a Ph.D. in Integrated Biomedical Sciences from the Ohio State University as well as a B.S.

Andrew Fisher Joins Verona Pharma as General Counsel

Retrieved on: 
Monday, March 4, 2024

LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team.

Key Points: 
  • LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team.
  • Mr. Fisher is an accomplished lawyer with more than 25 years of experience in the life sciences industry.
  • He brings a wealth of legal and strategic expertise supporting global, pre-clinical and clinical development, manufacturing and commercialization including launching four pulmonary therapies.
  • Dr. Zaccardelli added: “We would like to thank Claire for her leadership and recognise her significant contributions to Verona Pharma’s successful development since its inception.

NBME Hires New Vice President of Product Management and Innovation

Retrieved on: 
Tuesday, February 27, 2024

PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- NBME, a leading medical assessment company, has hired Laura Ryan as Vice President of Product Management & Innovation in its Growth and Innovation division.

Key Points: 
  • PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- NBME, a leading medical assessment company, has hired Laura Ryan as Vice President of Product Management & Innovation in its Growth and Innovation division.
  • Ryan brings over 18 years of experience in product management, health care education and relationship management to her new role.
  • “Laura is a fantastic leader who is deeply invested in improving patient care through her work building digital assessments and tools that deliver information and insights to health care professionals,” Pamela Treves, NBME Senior Vice President of Growth and Innovation, said.
  • “She will play an integral role in enhancing our product portfolio and we are delighted to have her on board.”
    Ryan will place NBME’s medical learners, educators, and partners at the center of her innovation and product strategy.

Evidence review: Maternal mental conditions drive climbing death rate in U.S.

Retrieved on: 
Wednesday, February 21, 2024

“The contribution of mental health conditions to the maternal morbidity and mortality crisis that we have in America is not widely recognized,” said Katherine L. Wisner, M.D.

Key Points: 
  • “The contribution of mental health conditions to the maternal morbidity and mortality crisis that we have in America is not widely recognized,” said Katherine L. Wisner, M.D.
  • , associate chief of Perinatal Mental Health and member of the Center for Prenatal, Neonatal & Maternal Health Research at Children’s National.
  • Overdose and other maternal mental health conditions are taking the lives of more than twice as many women as postpartum hemorrhage, the second leading cause of maternal death.
  • Mental health conditions such as suicide or opioid overdose are to blame for nearly 23% of maternal deaths in America, according to reports from three dozen Maternal Morbidity and Mortality Review Committees, which are state-based organizations that review each maternal death within a year of pregnancy.

Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion

Retrieved on: 
Thursday, February 29, 2024

2023 margin expansion was driven by gains from premiumization, structural cost savings, and operating expenses leverage, partially offset by nemolizumab investments.

Key Points: 
  • 2023 margin expansion was driven by gains from premiumization, structural cost savings, and operating expenses leverage, partially offset by nemolizumab investments.
  • On 26 June 2023, Galderma announced a private placement of approximately 1 B USD from a group consisting of current shareholders, new investors, as well as management.
  • Cetaphil, with over 75 years of heritage in sensitive skincare, surpassed a record 1 B USD in net sales in 2023.
  • In 2023, Galderma further consolidated its ESG profile by rolling out a dedicated executive-level ESG oversight and instituting the ESG Council.

H2O.ai Inaugurates GenAI World for Public Sector to Spur Growth and Innovation of Generative AI for Government Departments and Agencies

Retrieved on: 
Tuesday, February 27, 2024

H2O.ai, the open source leader in Generative AI and machine learning, continues its world tour of bringing GenAI World conferences to new sectors to further democratize AI.

Key Points: 
  • H2O.ai, the open source leader in Generative AI and machine learning, continues its world tour of bringing GenAI World conferences to new sectors to further democratize AI.
  • An Overview of the NIST AI Risk Management Framework by Patrick Hall, Professor for AI Risk, The George Washington University.
  • These training sessions will cover GenAI use cases using public sector data, LLM benchmarking and evaluation best practices, GenAI interpretability, governance frameworks and model validation.
  • Founded in 2012, H2O.ai is at the forefront of the AI movement to democratize Generative AI.

Wai Ming Lau Elected Chairman of the Board of Directors of Deswell Industries

Retrieved on: 
Monday, February 26, 2024

Deswell Industries, Inc. (Nasdaq: DSWL) is pleased to announce that the Board of Directors has unanimously elected Ms. Lau Wai Ming as Chairman of the Board, effective February 19, 2024.

Key Points: 
  • Deswell Industries, Inc. (Nasdaq: DSWL) is pleased to announce that the Board of Directors has unanimously elected Ms. Lau Wai Ming as Chairman of the Board, effective February 19, 2024.
  • Ms. Lau was elected to the Board of Directors by the Company’s shareholders at the 2023 Annual Meeting of Shareholders on February 6, 2024.
  • Prior to joining the Company, Ms. Lau was an Executive Director at PAG Consulting where she headed the firm’s Global Human Capital operations.
  • Prior to PAG Consulting, Ms. Lau worked at Goldman Sachs for over 13 years, including serving as an Executive Director in Goldman Sachs’ Finance Division.

Cenlar Appoints Seasoned Leaders to the Corporate Initiatives Group

Retrieved on: 
Monday, February 26, 2024

Cenlar FSB, the nation’s leading mortgage loan subservicer, announced today the appointment of Catherine French to Senior Vice President and Head of the company’s Corporate Initiatives Group.

Key Points: 
  • Cenlar FSB, the nation’s leading mortgage loan subservicer, announced today the appointment of Catherine French to Senior Vice President and Head of the company’s Corporate Initiatives Group.
  • As Senior Vice President and Head of the Corporate Initiatives Group, Catherine will spearhead the Strategic Initiatives team, Enterprise Portfolio Management, and Strategic Sourcing and Procurement.
  • As a Senior Vice President in the Strategic Initiatives team, Julie will partner with leaders to improve and enhance operational excellence around homeowner correspondence.
  • As Vice President in the Strategic Initiatives team, Himanshu will partner with leaders to drive initiatives around Cenlar’s client facing data, analytics, and other risk-related activities.